Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
Keywords:
Non-hodgkin diffuse large B-cell lymphoma
Follicular lymphoma
Rituximab
Safety
Administration-related reactions
Note:
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Citation:
Garcia-Muñoz, R. (R.); Quero, C. (C.); Pérez-Persona, E. (Ernesto); et al. "Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study". British journal of haematology. 188 (5), 2020, 661 - 673
Statistics and impact
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.